

Cite this: *Dalton Trans.*, 2022, **51**, 6153Received 10th March 2022,  
Accepted 23rd March 2022DOI: [10.1039/d2dt00772j](https://doi.org/10.1039/d2dt00772j)[rsc.li/dalton](https://rsc.li/dalton)Toward asymmetric aziridination with an iron complex supported by a  $D_2$ -symmetric tetra-NHC†Kevin M. Blatchford, Carson J. Mize,  Sharani Roy  and David M. Jenkins \*

A neutral  $D_2$ -symmetric macrocyclic tetra-N-heterocyclic carbene ligand was synthesized. The macrocycle was ligated to iron(II) via transmetalation from an isolated silver complex that has two conformers. The iron complex catalyzed the first stereospecific aziridination between aryl azides and aliphatic alkenes, albeit with low ee's.

Catalytic  $C_2 + N_1$  aziridination has undergone a revival in the last decade with the development of multiple approaches to form a three membered ring from a nitrene source ( $N_1$ ) and an alkene ( $C_2$ ).<sup>1–7</sup> This research is driven by two competing dynamics: aziridines are effective reagents in organic synthesis due to their strained ring,<sup>8,9</sup> but, unlike epoxides, there are no effective commercial aziridination catalysts across a variety of alkenes.

Most alkenes are prochiral, and thus either one or two chiral carbons are set during the catalytic reaction, yet even with some recent advances, catalytic synthesis of asymmetric aziridines remains highly limited.<sup>4,6,7</sup> Researchers including Zhang, Schomaker, Katsuki, and Uchida have developed catalysts that produce single enantiomers, but with limitations such as performing only with very specific reagents like styrene and its derivatives for the alkene, or only working with (tosylimino)benzene as the nitrene source.<sup>2,10–14</sup> This lack of stereo control is a pity, since many medicinal or biological applications benefit from forming a single enantiomer.<sup>15,16</sup>

Our group has developed macrocyclic tetra-NHC complexes on both iron and chromium that are effective for catalytic aziridination with organic azides and aliphatic alkenes.<sup>17–19</sup> Recently, we developed a synthesis of the first  $D_2$ -symmetric chiral macrocyclic NHC by linking  $C_2$ -symmetric chiral diimidazoles bound on a cyclohexyl ring.<sup>20</sup> We hypothesized that a

similar, less sterically hindered,  $D_2$ -symmetric macrocycle could produce an iron complex that would favour one enantiomer in a catalytic aziridination reaction.

In this manuscript, we report the synthesis of the first catalyst that gives enantiomeric excess of chiral aziridines prepared from aryl azides and aliphatic alkenes. Our approach was to prepare a new, more flexible,  $D_2$ -symmetric tetra-imidazolium macrocycle that was then complexed to silver forming two distinct stereoisomeric dimers, both of which were effective in NHC transmetalation to iron. The iron complex was modestly effective as an aziridination catalyst and, in cases with *ortho* substituents on the aryl ring of the organic azide, measurable ee's for the aziridines were obtained. Computational results suggest that this approach is feasible with a limited scope of organic azides and provides suggestions about how to develop an improved future catalyst.


The ability to synthesize the desired  $D_2$ -symmetric tetra-imidazolium macrocycle requires the synthesis of  $C_2$ -symmetric diimidazoles. We had previously reported a two-step synthesis of (1*S*,2*S*)-1,2-di(imidazole)cyclohexane from its commercially available chiral diamine<sup>20</sup> and a similar strategy proved successful here (Scheme 1A). Addition of 1,1-diethoxy-2-isothiocyanatoethane to (1*S*,2*S*)-(-)-1,2-diphenylethylenediamine in refluxing dry acetonitrile followed by addition of 1 M HCl led to the formation of 1,1'-((1*S*,2*S*)-1,2-diphenylethane)bis(1,3-dihydro-2*H*-imidazole-2-thione), **1**. Compound **1** was isolated by precipitation at –20 °C and then washed with water to produce the pure product in 94% yield. Thione **1** was reduced to the diimidazole by addition of HNO<sub>3</sub> and NaNO<sub>2</sub> at 0 °C. After the reaction was completed, the product was extracted with CH<sub>2</sub>Cl<sub>2</sub> from the aqueous layer and 1,1'-[(1*S*,2*S*)-1,2-diphenyl-1,2-ethanediyl]bis-imidazole (**2**) was purified with gradient column chromatography on silica gel (MeOH/CH<sub>2</sub>Cl<sub>2</sub>) giving a 45% yield. Notably, diimidazole **2** can be synthesized on a 5+ gram scale.

The chiral macrocycle (<sup>*S,S*</sup>-1,2-Ph<sub>2</sub>-Et, Me<sub>2</sub>TC<sup>H</sup>)(OTf)<sub>4</sub>, **3**, was formed by reaction of **2** with ditriflatomethane<sup>21</sup> in dry acetonitrile at 0 °C for 12 hours (Scheme 1A). The solvent was

Department of Chemistry, University of Tennessee, Knoxville, Tennessee 37996, USA.  
E-mail: [jenkins@ion.chem.utk.edu](mailto:jenkins@ion.chem.utk.edu)

† Electronic supplementary information (ESI) available: Complete experimental details, NMR, IR, MS, and DFT calculations. CCDC 2152673–2152677. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d2dt00772j>





**Scheme 1** (A) Synthesis of  $D_2$ -symmetric macrocyclic tetra-imidazolium. (B) Synthesis of chiral iron catalyst (7). Complex 6 is a mixture of conformers; **6a** is shown.

removed under reduced pressure and the collected solid was washed with THF to yield pure **3** in 45% yield. To prevent anion confusion, we completed two ion exchange steps, *via*  $(^{(S,S)}\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H)(\text{I})_4$  (**4**), to replace the triflate anion with  $\text{PF}_6$ , giving  $(^{(S,S)}\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H)(\text{PF}_6)_4$  (**5**) (see ESI for details<sup>†</sup>).

Crystallographic and spectroscopic characterization of **5** involved several notable features. First, single crystal X-ray diffraction of **5** confirms the absolute stereochemistry as  $(S,S,S,S)$  (Fig. 1A). Second, the  $^1\text{H}$  NMR and HSQC spectra for **5** shows the stereogenic protons at 6.31 ppm (Fig. S17 and S19<sup>†</sup>) suggesting that they are highly acidic compared to our original macrocycle,  $(^{\text{Et,Me}}\text{TC}^H)(\text{OTf})_4$ , which shows resonances for the ethyl bridging protons at 4.68 ppm.<sup>22</sup>

The relatively similar  $\text{pK}_a$ s for the stereogenic protons on the ethyl bridge and for the imidazolium protons prevented us from employing a direct deprotonation strategy for the macrocyclic ligand.<sup>18,21,23</sup> Instead, we synthesized a silver complex to act as a transmetalation reagent, a strategy we previously employed with  $(^{\text{Et,Me}}\text{TC}^H)(\text{PF}_6)_4$ .<sup>22,23</sup> Combining **5**,  $\text{AgPF}_6$ , and  $\text{NEt}_3$  in  $\text{DMSO}$  at  $90^\circ\text{C}$  for 48 hours gave a brown solution. The product,  $[(^{(S,S)}\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H)_2\text{Ag}_4](\text{PF}_6)_4$  (**6**), was precipitated by addition of excess DI water to give a 45% yield. The initial analysis of the  $^1\text{H}$  NMR of the product (Fig. S23<sup>†</sup>) was highly perplexing until we realized that two separate conformers were formed. The conformers were separated by selective solvent extraction and confirmed by single crystal X-ray diffraction. The solid-state structure of the eclipsed conformer, designated as **6a**, is shown in Fig. 1B, while the staggered conformer, **6b**, where the macrocycles are rotated  $90^\circ$  *versus* each other is shown in Fig. S57.<sup>†</sup> Both conformers, **6a** and **6b**, retain the all- $S$  chiral configuration.


The iron complex,  $[(^{(S,S)}\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H)\text{Fe}(\text{NCCCH}_3)_2](\text{PF}_6)_2$  (**7**), was synthesized directly from **6** without the need to separate the conformers. Complex **6** and  $\text{FeI}_2$  were mixed in acetonitrile for 48 hours at  $25^\circ\text{C}$ , which gave **7** in 95% yield after

crystallization by vapor diffusion. Complex **7** is diamagnetic and the  $^1\text{H}$  NMR shows that it is rigid, giving diastereotopic protons on the methyl bridges at 6.24 and 5.79 ppm (Fig. S33<sup>†</sup>). The proton resonances off the stereogenic carbons in **7** are 6.88 and 6.79 ppm and are confirmed by HSQC (Fig. S35<sup>†</sup>). The X-ray crystal structure of **7** confirms the  $C_2$ -symmetry of the iron complex (Fig. 1C). Two separate iron complexes were identified in the asymmetric unit, but both are structurally similar and have the same all- $S$  chirality. Like similar iron complexes ligated to neutral NHC macrocycles, the Fe–C bond distances are between 1.92 and 2.00 Å, and acetonitrile ligands bind to the axial positions in the octahedral geometry.<sup>18,21,24,25</sup>


Since our group has been developing aziridination catalysis with aryl azides and aliphatic alkenes, we decided to focus on straight chain alkenes for initial tests as the resulting aziridines would have only a single chiral carbon (Scheme 2). Our initial test reaction with *p*-tolyl azide, 1-decene and **7** as the catalyst yielded 2-octyl-1-(*p*-tolyl)aziridine, **8**, in 55% isolated yield after column chromatography on silica gel (Table 1, entry 1). Unlike epoxides, where there are many standard examples for determining effective chiral catalysts, there are so few examples for similar aziridines that we did not have a standard protocol for chiral separation of the enantiomers. We were able to separate the enantiomers consistently for the aziridines with ultra-high performance liquid chromatography (UHPLC) with a Phenomenex Lux 3  $\mu\text{m}$  Cellulose-1 column with a mixture of acidified acetonitrile and water (see ESI for complete details<sup>†</sup>). Unfortunately, the UHPLC showed no enantiomeric excess for **8** (Fig. S43<sup>†</sup>). Substituting to a shorter alkene, 1-octene, had no significant difference in the result (Table 1, entry 2).

Switching to an *ortho*-substituted aryl azide, on the other hand, had significant impact on the catalytic reaction. A reaction with *o*-tolyl azide, 1-octene and **7** as the catalyst yielded 2-hexyl-1-(*o*-tolyl)aziridine, **10**, in 64% isolated yield after





**Fig. 1** Solid state structures of (A)  $[(S,S)\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H](\text{PF}_6)_4$ , **5**, (B)  $[(S,S)\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H]_2\text{Ag}_4(\text{PF}_6)_4$ , **6a**, and (C)  $[(S,S)\text{-}1,2\text{-Ph}_2\text{-Et,MeTC}^H]\text{Fe}(\text{NCCH}_3)_2(\text{PF}_6)_2$ , **7**. Green, burgundy, blue, grey, and white ellipsoids (50% probability) represent Ag, Fe, N, C, and H atoms, respectively. Solvent molecules and H-atoms on non-stereogenic atoms are omitted for clarity; Selected bond lengths (Å) and angles (°) are as followed for **6a**: Ag–C1, 2.107(3); Ag–C5, 2.093(3); C1–Ag–C5, 168.5(1) and **7**: Fe2–C47, 2.001(6); Fe2–C48, 1.937(7); Fe2–C49, 1.992(6); Fe2–C50, 1.923(6); C47–Fe2–C49, 170.2(2); C48–Fe2–C50, 177.2(3); N19–Fe2–N20, 178.7(2).



**Scheme 2** Catalytic aziridination reactions with **7**. \* Denotes chiral carbon.

column chromatography (Table 1, entry 3). Notably, UHPLC showed a clear, but small, differentiation between the enantiomers in this case with a 3% ee based on integration of the

**Table 1** Testing different azides and alkenes for aziridination

Entry <sup>a</sup>	Aziridine	<i>n</i>	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Isolated yield (%)	ee by UHPLC <sup>b</sup> (%)
1	<b>8</b>	7	Me	H	H	55	< 2
2	<b>9</b>	5	Me	H	H	65	< 2
3	<b>10</b>	5	H	Me	H	64	3
4	<b>11</b>	5	H	<sup>i</sup> Pr	H	15	4
5	<b>12</b>	5	Me	Me	Me	—	—

<sup>a</sup> Between 50–70 mg of each azide was used in every reaction. Catalyst loading was 2% for each reaction. <sup>b</sup> A measured ee needed to be greater than 2% to be reported, even if integrations were not exactly equivalent.


peaks (Fig. S50†). Increasing the steric bulk in the *ortho* position to isopropyl gave similar results for ee but with a reduced yield (Table 1, entry 4). Nevertheless, formation of 2-hexyl-1-(2-isopropylphenyl)aziridine, **11**, confirmed that the enantioselective catalysis is compatible with multiple R-groups. At present, we have not been able to determine which enantiomer of the aziridines are favoured, since **10** and **11** are liquids and similar chiral aziridines have not been reported in the literature allowing for comparison by optical rotation.

Two additional organic azides were attempted which also showed the limitations of catalyst **7**. First, a reaction with mesityl azide showed no reaction with the iron complex (Table 1, entry 5). Steric bulk in both *ortho* positions of the aryl ring shuts down catalysis. Second, complex **7** does not react with alkyl azides, such as octyl azide, which is consistent with our previous reports on catalysts supported by neutral NHC-macrocycles.<sup>18,19</sup>

To help elucidate these experimental results, we investigated some of these reaction profiles by DFT (see ESI for details†). In our previous publication on the mechanism of aziridination with iron catalysts, we noted that there are two key transition states.<sup>26</sup> First, the addition of organic azide to iron complex forms an imide. Second, the addition of alkene to the iron imide gives a short-lived metalloradical intermediate, which subsequently quickly ring closes over a small energy barrier to form the aziridine. Adding steric bulk to form the C<sub>2</sub>-symmetric pocket about iron increases the activation free energy of the initial imide-forming step. For mesityl azide, the calculated free-energy barrier is 27.9 kcal mol<sup>-1</sup>, whereas for *p*-tolyl azide and *o*-tolyl azide, the free-energy barriers are 20.7 kcal mol<sup>-1</sup> and 21.2 kcal mol<sup>-1</sup>, respectively. This result explains why we saw no reactivity with mesityl azide and **7** (Fig. S58 and Table S1†) and also explains the high temperatures required for the catalytic reaction.

More promisingly, DFT calculations do show a difference between the *R* and *S* enantiomers of the aziridine. The reaction profile for *p*-tolyl azide, 1-decene and **7** shows a  $\Delta\Delta G^\ddagger$  of 1.8 kcal mol<sup>-1</sup> difference between the free energies of activation for formation of the *R* and *S* enantiomers of **8** (Fig. 2) during the ring closing step. The energy gap must increase sufficiently to lead to a measurable ee for *ortho* substituted aryl rings.





**Fig. 2** DFT-computed free-energy pathway for formation of aziridine from *p*-tolyl imide and 1-decene using catalyst 7. All species are in  $S = 1$  (triplet) spin state, excluding the final aziridine product. TS designates a transition state. Free energies ( $\Delta G$ ) are given in kcal mol<sup>-1</sup>.

A final consideration for developing improved catalysts for aziridination also includes considering the relatively high activation energies. While organic azides are excellent choices from an atom economy perspective,<sup>1</sup> they can also form aziridines when heated in the presence of alkenes without a catalyst (often in low to modest yield).<sup>27,28</sup> For example, **8** is formed in 32% yield without a catalyst (see ESI†). To improve the ee's of subsequent catalysts, it will be necessary to reduce the TS energies significantly so that little to no background reaction is occurring.

In conclusion, we have synthesized a new  $D_2$ -symmetric tetra-NHC macrocycle and its subsequent silver and iron complexes. The absolute stereochemistry ( $S,S,S,S$ ) of the macrocycle and complexes was confirmed by single crystal X-ray diffraction. The iron complex demonstrated the proof of principle that these  $C_2$ -symmetric tetra-NHC complexes can favour one enantiomer over the other during the formation of aziridines from aryl azides and aliphatic alkenes, which, to our knowledge, has never been previously demonstrated. Finally, DFT calculations suggest that lowering the energy of the TS1 in Fig. 2 will be necessary to improve the ee's of the reactions by making the catalysis even more favourable than the background reaction, which is crucial for forming a single enantiomer.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank Xian Carroll for helpful discussions on X-ray crystallography. We thank Lindsay Brown from the Biological and Small Molecule Mass Spectrometry Core Facility for assistance on measurement of the MS of the aziridines. K.M.B. and D.M.J. are grateful to the National Institute of General Medical Sciences (R15GM117494-02) for financial support. C.J.M., S.R.,

and D.M.J. are grateful to the NIH (R15GM117494-01A) for financial support.

## Notes and references

- 1 D. M. Jenkins, *Synlett*, 2012, 1267–1270.
- 2 L.-M. Jin, X. Xu, H. Lu, X. Cui, L. Wojtas and X. P. Zhang, *Angew. Chem., Int. Ed.*, 2013, **52**, 5309–5313.
- 3 K.-H. Chan, X. Guan, V. K.-Y. Lo and C.-M. Che, *Angew. Chem., Int. Ed.*, 2014, **53**, 2982–2987.
- 4 M. Ju and J. M. Schomaker, *Nat. Rev. Chem.*, 2021, **5**, 580–594.
- 5 C. Damiano, S. Gadolini, D. Intriери, L. Lay, C. Colombo and E. Gallo, *Eur. J. Inorg. Chem.*, 2019, **2019**, 4412–4420.
- 6 H. Pellissier, *Adv. Synth. Catal.*, 2014, **356**, 1899–1935.
- 7 L. Degennaro, P. Trinchera and R. Luisi, *Chem. Rev.*, 2014, **114**, 7881–7929.
- 8 D. Tanner, *Angew. Chem., Int. Ed. Engl.*, 1994, **33**, 599–619.
- 9 R. Akhtar, S. A. R. Naqvi, A. F. Zahoor and S. Saleem, *Mol. Diversity*, 2018, **22**, 447–501.
- 10 V. Subbarayan, J. V. Ruppel, S. Zhu, J. A. Perman and X. P. Zhang, *Chem. Commun.*, 2009, 4266–4268.
- 11 M. Ju, C. D. Weatherly, I. A. Guzei and J. M. Schomaker, *Angew. Chem., Int. Ed.*, 2017, **56**, 9944–9948.
- 12 H. Nishikori and T. Katsuki, *Tetrahedron Lett.*, 1996, **37**, 9245–9248.
- 13 K. Noda, N. Hosoya, R. Irie, Y. Ito and T. Katsuki, *Synlett*, 1993, 469–471.
- 14 K. Omura, T. Uchida, R. Irie and T. Katsuki, *Chem. Commun.*, 2004, 2060–2061.
- 15 T. J. Hodgkinson and M. Shipman, *Tetrahedron*, 2001, **57**, 4467–4488.
- 16 M. Kasai and M. Kono, *Synlett*, 1992, 778–790.
- 17 C. L. Keller, J. L. Kern, B. D. Terry, S. Roy and D. M. Jenkins, *Chem. Commun.*, 2018, **54**, 1429–1432.
- 18 S. A. Cramer and D. M. Jenkins, *J. Am. Chem. Soc.*, 2011, **133**, 19342–19345.
- 19 P. P. Chandrachud, H. M. Bass and D. M. Jenkins, *Organometallics*, 2016, **35**, 1652–1657.
- 20 J. F. DeJesus and D. M. Jenkins, *Chem. – Eur. J.*, 2020, **26**, 1429–1435.
- 21 M. R. Anneser, S. Haslinger, A. Pothig, M. Cokoja, J. M. Basset and F. E. Kuhn, *Inorg. Chem.*, 2015, **54**, 3797–3804.
- 22 H. M. Bass, S. A. Cramer, J. L. Price and D. M. Jenkins, *Organometallics*, 2010, **29**, 3235–3238.
- 23 Z. Lu, S. A. Cramer and D. M. Jenkins, *Chem. Sci.*, 2012, **3**, 3081–3087.
- 24 A. A. Massie, C. Schremmer, I. Rüter, S. Dechert, I. Siewert and F. Meyer, *ACS Catal.*, 2021, **11**, 3257–3267.
- 25 M. A. Bernd, F. Dyckhoff, B. J. Hofmann, A. D. Böth, J. F. Schlagintweit, J. Oberkofler, R. M. Reich and F. E. Kühn, *J. Catal.*, 2020, **391**, 548–561.
- 26 S. B. Isbill, P. P. Chandrachud, J. L. Kern, D. M. Jenkins and S. Roy, *ACS Catal.*, 2019, **9**, 6223–6233.
- 27 P. Scheiner, *Tetrahedron*, 1968, **24**, 349–356.
- 28 J. B. Sweeney, *Chem. Soc. Rev.*, 2002, **31**, 247–258.

